Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474
Authors:
- Annelot C. M. van EsbroeckAEAnnelot C. M. van Esbroeck
- Antonius P. A. JanssenAJAntonius P. A. Janssen
- Armand B. CognettaACArmand B. Cognetta
- Daisuke OgasawaraDODaisuke Ogasawara
- Guy ShpakGSGuy Shpak
- Mark van der KroegMKMark van der Kroeg
- Vasudev KantaeVKVasudev Kantae
- Marc P. BaggelaarMBMarc P. Baggelaar
- Femke M. S. de VrijFVFemke M. S. de Vrij
- Hui DengHDHui Deng
- Marco AllaràMAMarco Allarà
- Filomena FezzaFFFilomena Fezza
Top Cited Papers
- 9 June 2017
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6342) , 1084-1087
Abstract
A clue to a drug's neurotoxicity?: The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered brain damage. As an initial step in investigating whether inhibition of off-target proteins by BIA 10-2474 might contribute to its clinical neurotoxicity, van Esbroeck et al. used activity-based proteomic assays to identify proteins targeted by the drug. Studying human cells and brain samples from subjects not associated with the trial, they found that BIA 10-2474 targeted several different lipases in addition to FAAH. It also substantially altered lipid metabolism in cultured neurons. Science , this issue p. 1084Keywords
Funding Information
- National Institutes of Health (award304469, DA033760)
This publication has 39 references indexed in Scilit:
- Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide HydrolaseNew England Journal of Medicine, 2016
- Implications of the BIA‐102474‐101 study for review of first‐into‐human clinical trialsBritish Journal of Clinical Pharmacology, 2016
- Scientists in the dark after French clinical trial proves fatalNature, 2016
- An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the kneePain, 2012
- Assessment of the pharmacology and tolerability of PF‐04457845, an irreversible inhibitor of fatty acid amide hydrolase‐1, in healthy subjectsBritish Journal of Clinical Pharmacology, 2012
- Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivoProceedings of the National Academy of Sciences, 2009
- Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channelsThe EMBO Journal, 2005
- Modulation of anxiety through blockade of anandamide hydrolysisNature Medicine, 2002
- Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amidesNature, 1996
- Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid ReceptorScience, 1992